Anamorelin

At Verified Peptides, we believe in transparent classification, so we want to state this plainly upfront: Anamorelin is a non-peptide small molecule, not a peptide. It is included in our Growth Hormone Secretagogue research category because it acts on the same ghrelin/growth hormone secretagogue receptor (GHSR) pathway that genuine peptide secretagogues target, but its own chemical structure is a synthetic small molecule rather than an amino acid chain. Researchers specifically seeking peptide compounds should be aware of this distinction before including Anamorelin in a peptide-focused research protocol.

Anamorelin (also known by its development codes RC-1291 and ONO-7643, and marketed as the hydrochloride salt) has the molecular formula C31H42N6O3 as the free base (PubChem CID 9828911) or C31H43ClN6O3 as the hydrochloride salt (PubChem CID 16072155, CAS 249921-19-5 for the HCl salt form). It is an orally bioavailable ghrelin receptor agonist developed originally by Helsinn Healthcare, studied primarily for cancer-associated cachexia (the severe muscle and fat wasting syndrome that accompanies advanced cancer).

Anamorelin has a genuinely distinctive regulatory profile among the compounds in our catalog: it is approved in Japan (since 2020) for the treatment of cachexia associated with several cancer types, making it one of the few compounds in this catalog with an existing drug approval anywhere in the world, while remaining unapproved in the United States.

Cancer cachexia itself remains an area with no FDA-approved pharmacological treatment in the United States as of this writing, despite affecting a substantial proportion of patients with advanced cancer and being independently associated with reduced treatment tolerance, reduced quality of life, and shortened survival. This regulatory gap is part of why Anamorelin’s research profile continues to draw attention even without U.S. approval -- it represents one of the more clinically advanced candidates addressing a condition that otherwise has few dedicated pharmacological options.

At Verified Peptides, we consider the ROMANA trial program the definitive published evidence base for Anamorelin. ROMANA 1 and ROMANA 2 (Lancet Oncology, 2016; PMID 26906526) were two randomized, double-blind, placebo-controlled Phase 3 trials conducted across 93 sites in 19 countries, enrolling patients with inoperable stage III or IV non-small-cell lung cancer and cachexia. ROMANA 1 randomized 484 patients (323 to anamorelin 100 mg orally once daily, 161 to placebo) and ROMANA 2 randomized 495 patients (330 to anamorelin, 165 to placebo). Both trials had co-primary endpoints of 12-week change in lean body mass and handgrip strength.

The lean body mass endpoint was met with strong statistical significance in both trials: ROMANA 1 showed a median increase of 0.99 kg with anamorelin versus a 0.47 kg decrease with placebo (p<0.0001), and ROMANA 2 showed a 0.65 kg increase versus a 0.98 kg decrease (p<0.0001). However, the handgrip strength endpoint was NOT met in either trial: ROMANA 1 showed no significant difference (-1.10 kg anamorelin vs -1.58 kg placebo, p=0.15), and ROMANA 2 likewise showed no significant difference (-1.49 kg vs -0.95 kg, p=0.65). We are reporting this split result plainly — a real, statistically significant body-composition effect alongside a real, statistically null functional-strength effect — rather than characterizing the trials as a simple, unqualified success.

A follow-on safety extension study, ROMANA 3 (PMID 28472437), allowed patients who completed 12 weeks in ROMANA 1 or ROMANA 2 with preserved functional status to continue anamorelin or placebo for an additional 12 weeks, providing longer-term safety data consistent with the earlier trials. More recent real-world postmarketing surveillance in Japan (PMID 38693813) has reported effectiveness and safety findings consistent with the pivotal trials in routine clinical use since Japanese approval.

Anamorelin is approved in Japan for cancer cachexia but has not been approved by the FDA in the United States as of this writing. Research-grade Anamorelin sold here is intended exclusively for laboratory research, not for human or animal use.

Anamorelin is one of the clearest examples in this catalog of a compound that succeeded on one co-primary trial endpoint while failing another — increasing lean body mass significantly while showing no improvement in handgrip strength. This dissociation has itself become an important research topic in the cachexia field: it raises the question of whether increasing muscle tissue quantity is sufficient on its own, or whether muscle quality, neuromuscular function, or physical activity levels also need to be addressed to translate mass gains into functional improvement — a question that remains actively debated rather than settled.

Despite being marketed and researched as part of the broader "ghrelin mimetic" and growth hormone secretagogue research space alongside genuine peptides, Anamorelin's own chemistry has no amino acid backbone at all. This makes it structurally more similar to other non-peptide GHSR agonists explored in pharmaceutical research than to peptide secretagogues like Ipamorelin, GHRP-2, or GHRP-6, even though all of these compounds are studied for converging effects on the same receptor.

Anamorelin's Japanese approval specifically covers cachexia associated with several cancer types, reflecting a regulatory pathway that recognized cancer cachexia as a distinct treatable condition in its own right, separate from the underlying cancer — a regulatory framing not yet mirrored in the United States, where no drug is currently FDA-approved specifically for cancer cachexia.

Cachexia research extends beyond cancer specifically, and Anamorelin along with related ghrelin-pathway compounds has drawn research interest in other muscle-wasting conditions such as chronic obstructive pulmonary disease (COPD) and HIV/AIDS-associated wasting, though the clinical trial evidence specifically supporting these additional indications is considerably less developed than the NSCLC cachexia data covered above.

The 2024 Japanese post-marketing surveillance study (PMID 38693813), covering 6,016 patients treated in routine clinical practice, provides a substantially larger real-world dataset than the original ROMANA registration trials, reporting treatment-related adverse effects in a small percentage of patients (most commonly hyperglycemia and nausea) and modest body-weight improvement sustained over 52 weeks -- a useful complement to the controlled trial data, since real-world surveillance captures a broader and less selected patient population than a randomized trial's enrollment criteria typically allow.

At Verified Peptides, we require independent third-party HPLC purity testing and mass spectrometry or equivalent analytical identity confirmation for every batch of research-grade Anamorelin we offer, with a Certificate of Analysis (COA) available for each lot. Because Anamorelin is a small molecule rather than a peptide, its synthesis and purification process differs meaningfully from the solid-phase peptide synthesis used for the amino-acid-chain compounds elsewhere in our catalog, and quality verification should reflect the analytical standards appropriate to small-molecule pharmaceutical chemistry.

We source exclusively from manufacturers operating under Good Manufacturing Practice (GMP)-aligned quality systems, and every lot is independently verified rather than accepted solely on a supplier's internal documentation. Researchers should request and review the specific COA for their lot, confirming both purity percentage and molecular identity, before use in any experimental protocol.

Because Anamorelin research often involves body-composition and metabolic endpoints that can be sensitive to even small formulation or purity variations, rigorous identity and purity verification remain just as important for this small-molecule compound as for any peptide in our catalog.

Anamorelin, as a small-molecule hydrochloride salt rather than a lyophilized peptide, generally has different storage characteristics than the amino-acid-chain compounds elsewhere in our catalog. It should be stored at room temperature or refrigerated as specified on the Certificate of Analysis for the specific lot, protected from light and moisture, and used within the documented stability window for that batch.

Because small-molecule compounds like Anamorelin are generally more chemically stable in solid form than reconstituted peptide solutions, storage requirements tend to be less stringent than for lyophilized peptides requiring cold-chain handling after reconstitution — but researchers should still follow the specific lot documentation rather than assuming stability based on general small-molecule chemistry principles alone.

As with any research compound, prolonged exposure to heat, direct light, or humidity can accelerate degradation and compromise the material's relevance to research applications. Following the lot-specific storage guidance provided with each order remains the most reliable way to preserve sample validity.